106 related articles for article (PubMed ID: 23167653)
1. Bombesin peptide antagonist for target-selective delivery of liposomal doxorubicin on cancer cells.
Accardo A; Mansi R; Salzano G; Morisco A; Aurilio M; Parisi A; Maione F; Cicala C; Ziaco B; Tesauro D; Aloj L; De Rosa G; Morelli G
J Drug Target; 2013 Apr; 21(3):240-249. PubMed ID: 23167653
[TBL] [Abstract][Full Text] [Related]
2. Peptide-modified liposomes for selective targeting of bombesin receptors overexpressed by cancer cells: a potential theranostic agent.
Accardo A; Salsano G; Morisco A; Aurilio M; Parisi A; Maione F; Cicala C; Tesauro D; Aloj L; De Rosa G; Morelli G
Int J Nanomedicine; 2012; 7():2007-17. PubMed ID: 22619538
[TBL] [Abstract][Full Text] [Related]
3. Easy formulation of liposomal doxorubicin modified with a bombesin peptide analogue for selective targeting of GRP receptors overexpressed by cancer cells.
Accardo A; Mannucci S; Nicolato E; Vurro F; Diaferia C; Bontempi P; Marzola P; Morelli G
Drug Deliv Transl Res; 2019 Feb; 9(1):215-226. PubMed ID: 30569349
[TBL] [Abstract][Full Text] [Related]
4. Comparative study on DOTA-derivatized bombesin analog labeled with 90Y and 177Lu: in vitro and in vivo evaluation.
Koumarianou E; Mikołajczak R; Pawlak D; Zikos X; Bouziotis P; Garnuszek P; Karczmarczyk U; Maurin M; Archimandritis SC
Nucl Med Biol; 2009 Aug; 36(6):591-603. PubMed ID: 19647165
[TBL] [Abstract][Full Text] [Related]
5. A study on the role of cholesterol and phosphatidylcholine in various features of liposomal doxorubicin: From liposomal preparation to therapy.
Farzaneh H; Ebrahimi Nik M; Mashreghi M; Saberi Z; Jaafari MR; Teymouri M
Int J Pharm; 2018 Nov; 551(1-2):300-308. PubMed ID: 30243944
[TBL] [Abstract][Full Text] [Related]
6. Breast cancer targeted chemotherapy based on doxorubicin-loaded bombesin peptide modified nanocarriers.
Wang C; Sun X; Wang K; Wang Y; Yang F; Wang H
Drug Deliv; 2016 Oct; 23(8):2697-2702. PubMed ID: 26203692
[TBL] [Abstract][Full Text] [Related]
7. Engineered breast tumor targeting peptide ligand modified liposomal doxorubicin and the effect of peptide density on anticancer activity.
Shahin M; Soudy R; Aliabadi HM; Kneteman N; Kaur K; Lavasanifar A
Biomaterials; 2013 May; 34(16):4089-4097. PubMed ID: 23465829
[TBL] [Abstract][Full Text] [Related]
8. Target selective micelles for bombesin receptors incorporating Au(III)-dithiocarbamato complexes.
Ringhieri P; Iannitti R; Nardon C; Palumbo R; Fregona D; Morelli G; Accardo A
Int J Pharm; 2014 Oct; 473(1-2):194-202. PubMed ID: 25014371
[TBL] [Abstract][Full Text] [Related]
9. Preclinical evaluation of a novel ¹¹¹In-labeled bombesin homodimer for improved imaging of GRPR-positive prostate cancer.
Carlucci G; Ananias HJ; Yu Z; Hoving HD; Helfrich W; Dierckx RA; Liu S; de Jong IJ; Elsinga PH
Mol Pharm; 2013 May; 10(5):1716-24. PubMed ID: 23590837
[TBL] [Abstract][Full Text] [Related]
10. Optimized thermosensitive liposomes for selective doxorubicin delivery: formulation development, quality analysis and bioactivity proof.
Levacheva I; Samsonova O; Tazina E; Beck-Broichsitter M; Levachev S; Strehlow B; Baryshnikova M; Oborotova N; Baryshnikov A; Bakowsky U
Colloids Surf B Biointerfaces; 2014 Sep; 121():248-56. PubMed ID: 25001189
[TBL] [Abstract][Full Text] [Related]
11. Liposomal doxorubicin circumvents PSC 833-free drug interactions, resulting in effective therapy of multidrug-resistant solid tumors.
Krishna R; Mayer LD
Cancer Res; 1997 Dec; 57(23):5246-53. PubMed ID: 9393743
[TBL] [Abstract][Full Text] [Related]
12. Preclinical comparison of (111)In-labeled DTPA- or DOTA-bombesin analogs for receptor-targeted scintigraphy and radionuclide therapy.
Breeman WA; de Jong M; Erion JL; Bugaj JE; Srinivasan A; Bernard BF; Kwekkeboom DJ; Visser TJ; Krenning EP
J Nucl Med; 2002 Dec; 43(12):1650-6. PubMed ID: 12468515
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo evaluation of a 64Cu-labeled polyethylene glycol-bombesin conjugate.
Rogers BE; Manna DD; Safavy A
Cancer Biother Radiopharm; 2004 Feb; 19(1):25-34. PubMed ID: 15068608
[TBL] [Abstract][Full Text] [Related]
14. Preparation and evaluation of bombesin peptide derivatives as potential tumor imaging agents: effects of structure and composition of amino acid sequence on in vitro and in vivo characteristics.
Okarvi SM; Jammaz IA
Nucl Med Biol; 2012 Aug; 39(6):795-804. PubMed ID: 22381782
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and evaluation of a technetium-99m labeled cytotoxic bombesin peptide conjugate for targeting bombesin receptor-expressing tumors.
Okarvi SM; Al Jammaz I
Nucl Med Biol; 2010 Apr; 37(3):277-88. PubMed ID: 20346867
[TBL] [Abstract][Full Text] [Related]
16. Which one performs better for targeted lung cancer combination therapy: pre- or post-bombesin-decorated nanostructured lipid carriers?
Du J; Li L
Drug Deliv; 2016 Jun; 23(5):1799-809. PubMed ID: 26455787
[TBL] [Abstract][Full Text] [Related]
17. A simple passive equilibration method for loading carboplatin into pre-formed liposomes incubated with ethanol as a temperature dependent permeability enhancer.
Wehbe M; Malhotra A; Anantha M; Roosendaal J; Leung AWY; Plackett D; Edwards K; Gilabert-Oriol R; Bally MB
J Control Release; 2017 Apr; 252():50-61. PubMed ID: 28286316
[TBL] [Abstract][Full Text] [Related]
18. Spacer site modifications for the improvement of the in vitro and in vivo binding properties of (99m)Tc-N(3)S-X-bombesin[2-14] derivatives.
Fragogeorgi EA; Zikos C; Gourni E; Bouziotis P; Paravatou-Petsotas M; Loudos G; Mitsokapas N; Xanthopoulos S; Mavri-Vavayanni M; Livaniou E; Varvarigou AD; Archimandritis SC
Bioconjug Chem; 2009 May; 20(5):856-67. PubMed ID: 19344122
[TBL] [Abstract][Full Text] [Related]
19. Co-delivery of Doxorubicin and Ceramide in a Liposomal Formulation Enhances Cytotoxicity in Murine B16BL6 Melanoma Cell Lines.
Chen L; Alrbyawi H; Poudel I; Arnold RD; Babu RJ
AAPS PharmSciTech; 2019 Feb; 20(3):99. PubMed ID: 30719596
[TBL] [Abstract][Full Text] [Related]
20. Preclinical pharmacokinetic, biodistribution, imaging and therapeutic efficacy of (177)Lu-Labeled glycated bombesin analogue for gastrin-releasing peptide receptor-positive prostate tumor targeting.
Lim JC; Cho EH; Kim JJ; Choi SM; Lee SY; Nam SS; Park UJ; Park SH
Nucl Med Biol; 2015 Mar; 42(3):234-41. PubMed ID: 25498002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
